{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:43:01Z","timestamp":1794109381767,"version":"4.8.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.104949","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:26:36Z","timestamp":1692977196000},"page":"104949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8048-6845","authenticated-orcid":false,"given":"Sedat","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena Destan","family":"Bunul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Ozen-Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Altunrende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"Tutuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Uygunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsen","family":"Akman-Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husnu","family":"Efendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10206","key":"10.1016\/j.msard.2023.104949_bib0001","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2023.104949_bib0002","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/cns.12992","article-title":"Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod","volume":"24","author":"Evangelopoulos","year":"2018","journal-title":"CNS Neurosci. Ther."},{"issue":"9","key":"10.1016\/j.msard.2023.104949_bib0003","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","article-title":"Severe exacerbation of multiple sclerosis following withdrawal of Fingolimod","volume":"39","author":"Fragoso","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2023.104949_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103278","article-title":"Factors associated with fingolimod rebound: a single center real-life experience","volume":"56","author":"Goncuoglu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104949_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2016.11.003","article-title":"Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis","volume":"11","author":"Gunduz","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104949_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102849","article-title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","volume":"50","author":"Kim","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9451","key":"10.1016\/j.msard.2023.104949_bib0007","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.msard.2023.104949_bib0008","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2023.104949_bib0009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104949_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"17","key":"10.1016\/j.msard.2023.104949_bib0011","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2023.104949_bib0012","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.msard.2023.104949_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.104949_bib0014","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104949_bib0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/1744666X.2022.2105205","article-title":"The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders","volume":"18","author":"Stathopoulos","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2023.104949_bib0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104949_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/NRL.0000000000000154","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu","year":"2018","journal-title":"Neurologist"},{"issue":"5","key":"10.1016\/j.msard.2023.104949_bib0018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"updated-by":[{"DOI":"10.1016\/j.msard.2024.105917","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:03:01Z","timestamp":1727452981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823004509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":18,"alternative-id":["S2211034823004509"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104949","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.msard.2024.105917","asserted-by":"object"}]},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104949"}}